This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
psoriasis
Psoriasis
Chronic skin disease driven by Th17/IL-17 axis, TNF-alpha, and keratinocyte hyperproliferation; thickened scaly erythematous plaques. IL-17 inhibitors (secukinumab, ixekizumab), IL-23 inhibitors (risankizumab), and anti-TNF (adalimumab) provide near-complete skin clearance.
Entry Metadata
| Field | Value |
|---|---|
| ID | psoriasis |
| Name | Psoriasis |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496-509. · PubMed 19641206
- Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis — results of two phase 3 trials. N Engl J Med. 2014;371(4):326-338. · PubMed 25007392
- Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650-661. · PubMed 30097359